0001453687-24-000027.txt : 20240104
0001453687-24-000027.hdr.sgml : 20240104
20240104170829
ACCESSION NUMBER: 0001453687-24-000027
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Blaine
CENTRAL INDEX KEY: 0001802188
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37798
FILM NUMBER: 24513145
MAIL ADDRESS:
STREET 1: C/O ARTARA THERAPEUTICS, INC.
STREET 2: 1 LITTLE WEST 12TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001453687
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-923-1400
MAIL ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC
DATE OF NAME CHANGE: 20090109
4
1
wk-form4_1704406090.xml
FORM 4
X0508
4
2024-01-02
0
0001453687
Cartesian Therapeutics, Inc.
RNAC
0001802188
Davis Blaine
C/O CARTESIAN THERAPEUTICS, INC.
704 QUINCE ORCHARD ROAD
GAITHERSBURG
MD
20878
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-01-02
4
A
0
2424000
0
A
2424000
D
Employee Stock Option (right to buy)
0.6552
2024-01-02
4
A
0
3110000
0
A
2034-01-01
Common Stock
3110000
3110000
D
Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.
This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.
Matthew Bartholomae, Attorney-in-Fact for Blaine Davis
2024-01-04